INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is one of the leading malignant diseases worldwide. As in other types of cancer, the lymphatic system is the primary pathway of metastasis for CRC. Lymph node status is commonly used to identify a patient\'s prognosis, tumor stage, and treatment modality \[[@R1]\]. Patients without lymph node metastasis are classified as UICC stage I or II, depending on the infiltration depth. These patients have a favorable prognosis, and adjuvant chemotherapy is restricted to particular risk situations \[[@R2]\]. Nevertheless, approximately 10% to 20% of colon cancer cases show an adverse clinical course. To date, there is no generally accepted diagnostic tool available that could predict which of those cases are vulnerable to developing progressive disease.

Lymphovascular invasion (LVI) is thought to be involved the progress of lymphatic metastasis. The National Comprehensive Cancer Network (NCCN) Guidelines defined several additional factors including LVI status to identify patients at an increased risk for progressive disease in stage II colorectal cancers \[[@R2]\]. However, it remains unclear whether lymphovascular invasion marks a poor prognosis for patients with CRC. Although some researchers have found that patients with LVI positive tumors have a worse prognosis than those with LVI negative tumors \[[@R3]--[@R5]\], other investigators have reported that LVI is of no prognostic significance \[[@R6], [@R7]\]. It would be of great value to detect whether LVI is associated with a worse prognosis, to be a supplement to existing staging systems to determine whether a patient is suitable for adjuvant treatment \[[@R8]\]. The present study was designed to systematically assess the association between LVI and the prognosis of early stage (stage I/II) CRC patients.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

A total of 939 studies were retrieved from the database search, of which 513 studies were excluded as duplicates, 557 as inappropriate publication types, insufficient data or unrelated to stage I/II CRC. 79 full-text publications were left over to assess the eligibility. One study failed to get full-text was included due to a great number of sample size and sufficient data calculated from abstract \[[@R9]\]. Eventually, 19 articles met the inclusion criteria and were included in the analysis \[[@R7], [@R9]--[@R26]\]. Figure [1](#F1){ref-type="fig"} demonstrates the detailed process of articles identification and selection.

![Flow diagram of literature search and study selection](oncotarget-08-46565-g001){#F1}

Baseline characteristics of included studies {#s2_2}
--------------------------------------------

Overall, 9881 stage I/II CRC patients were included. A summary of the characteristics of all included studies were exhibited in Table [1](#T1){ref-type="table"}. Among the included 19 articles with sample sizes ranging from 82 to 2649 patients (median = 341), 9 studies (4068 patients, 41.17 %) were based on Asian populations; the remaining 10 studies (5813 patients, 58.83 %) were performed in non-Asian populations. The incidence of lymphovascular invasion ranges from 5.2% to 30.3%, and it was significantly higher in non-Asian region than in Asian region (*P* \< 0.05). Nine studies included colon cancer \[[@R13]--[@R16]\], 3 included rectal cancer and 7 included total colorectal cancer (without distinguishing colon and rectal cancer) \[[@R13]--[@R16]\]. The study quality scores, evaluated by the NOS, ranged from 5 to 8 (with a mean of 6.3), except one study that could not be analyzed because of only access to abstract \[[@R9]\]. Nine studies reported OS and 13 reported DFS as the prognostic indicator.

###### demonstrates the detailed process of articles identification and selection

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author    Published year   Region      Number\         Age mean±SD/\     Follow up(m) mean±SD/\   Tumor site   Number LVI+ (%)   nCRT   pCRT   TNM stage   Outcome   SQ^a^
                                         (male/female)   median (range)    median (range)                                                                              
  --------- ---------------- ----------- --------------- ----------------- ------------------------ ------------ ----------------- ------ ------ ----------- --------- -------
  Ghosh     2016             Australia   690(393/297)    NR                53.5(34-65)              C            209(30.3)         NR     NR     II          DFS       5

  Nikberg   2016             Sweden      2649(NA)        NA                NA                       R            387(14.6)         P      P      II          DFS       NA

  Zhang     2016             China       333(188/145)    63(17-86)         52.23±29.7               C            40(12.0)          N      P      II          OS        8

  Peng      2014             Australia   458(252/206)    73(23-97)         62.4(1.3-126)            C            115(25.1)         N      P      II          OS        8

  Patel     2014             US          175(95/80)      65(24-89)         720                      R            24(13.7)          N      N      I           OS        6

  Du        2014             China       145(84/61)      69(21-82)         68.5(6-120)              C            10(6.9)           N      N      I/II        DFS       8

  Lin       2014             Taiwan      962(612/350)    71.8(24-107)      60.2(4-106)              CR           50(5.2)           N      N      II          DFS       7

  Artac     2014             Turkey      554(332/222)    62(26-88)         NR                       C            107(19.3)         N      P      II          DFS       7

  Venook    2013             US          690(360/330)    NR                NR                       C            78(11.3)          NR     P      II          DFS       5

  Betge     2012             Austria     120(61/59)      71.2(33.4-85.2)   83(1-180)                CR           26(21.7)          N      NR     II          OS/DFS    7

  Barresi   2012             Italy       82(45/37)       70(48-89)         NR                       CR           23(28.0)          N      N      I           OS        5

  Choi      2010             Hong Kong   664(385/279)    70(27-96)         44(12-104)               CR           88(13.3)          NR     P      II          DFS       7

  Lim       2010             Korea       903(NR)         NR                87.5(3-120)              CR           95(10.5)          N      P      II          OS/DFS    6

  Huh       2010             Korea       341(209/132)    63.1(22-85)       57.6(0.4-106.2)          CR           44(12.9)          N      P      II          DFS       6

  Lin CC    2009             Taiwan      375(274/101)    68.3±12.1         48.5(0.7-96.6)           C            22(5.9)           NR     P      II          DFS       7

  Earle     2009             US          258(139/119)    NR                NR                       C            63(24.4)          N      P      II          OS        6

  Lee       2006             Korea       121(89/32)      57.7(28-80)       NR                       CR           25(12.9)          NR     P      I/II        DFS       6

  Law       2005             Hong Kong   224(141/83)     69(27-89)         NR                       R            29(12.9)          NR     NR     II          OS/DFS    6

  Lennon    2003             US          137(79/39)      70(36-90)         72(36-108)               C            34(24.8)          NR     NR     II          OS        4
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AJCC American Joint Committee on Cancer, R rectum, C colon, CR colorectum, DFS disease-free survival, N none of patients accept the therapy, nCRT neoadjuvant chemoradiotherapy, NR not reported, NA not access, OS overall survival, P part of patients accept the therapy, pCRT postoperative chemoradiotherapy, LVI+ the colorectal cancer patient with lymphovascular invasion positive, SD standard deviation, SQ score of study quality,

^a^ Study quality was judged based on the Newcastle-Ottawa Scale

Data analysis {#s2_3}
-------------

### LVI and OS in CRC {#s2_3_1}

A meta-analysis of 9 studies on OS demonstrated that LVI positive is associated with poor prognosis in CRC patients with stage I/II (HR = 2.15, 95 % CI = 1.72-2.68, *P* \< 0.01; Figure [2](#F2){ref-type="fig"}) using a fixed-effect model for no significant heterogeneity observed (*I*2 = 46 %, *P* = 0.06). DFS data were calculated from 13 studies by the fixed-effect model. Pooled analysis showed a significant association between LVI and DFS (HR = 1.73, 95% CI = 1.50-1.99, *P* \< 0.01; Figure [3](#F3){ref-type="fig"}) with no significant heterogeneity observed (*I*2 = 6%, *P* = 0.38).

![Forest plot of the hazard ratio for the association of lymphovascular invasion with overall survival in colorectal cancer patients](oncotarget-08-46565-g002){#F2}

![Forest plot of the hazard ratio for the association of lymphovascular invasion with disease free survival in colorectal cancer patients](oncotarget-08-46565-g003){#F3}

To distinguish between stage I and II, subgroup analysis by stage of TNM was conducted. In stage I group, only OS data were available. The result showed LVI positive was not associated with poor OS using a random-effect model (HR = 2.16, 95 % CI: 0.90-5.16, *P* = 0.08). However, LVI predicted poor OS and DFS in stage II group using a random-effect model (OS: HR = 2.45, 95 % CI: 1.65-3.64, *P* \< 0.01; DFS: HR = 1.71, 95 % CI: 1.48-1.98, *P* \< 0.01).

Furthermore we performed other subgroup analysis by district (Asian *vs*. non-Asian patients), LVI positive rate (≤15 *vs*. \> 15 %), sample sizes (≤190 *vs*. \> 200), tumor site (colon *vs*. rectum *vs*. colorectum) and study quality (≤6 *vs*. \> 6), neither of which alter the prognostic role of LVI in OS/DFS. (Table [2](#T2){ref-type="table"})

###### Results of overall and subgroup analyses for effects of LVI on overall and disease-free survival in colorectal cancer

  Categories                             *N*   Patients   Pooled HR(95 % CI)   *P* value   Heterogeneity   Model used   
  -------------------------------------- ----- ---------- -------------------- ----------- --------------- ------------ -----
  Overall survival (OS)                  9     2690       2.39(1.70-3.36)      \<0.01      46              0.06         FEM
  Subgroup 1: Asian                      3     1460       2.70(1.27-5.73)      0.01        82              \<0.01       REM
  Non-Asian                              6     1230       2.27(1.56-3.30)      \<0.01      0               0.61         REM
  Subgroup 2: LVI positive rate \>15 %   5     1055       2.45(1.64-3.65)      \<0.01      0               0.63         REM
  LVI positive rate ≤15 %                4     1635       2.38(1.28-4.43)      \<0.01      74              \<0.01       REM
  Subgroup 3: sample size\>200           4     1952       2.33(1.37-3.96)      \<0.01      71              0.02         REM
  Sample size≤200                        5     738        2.63(1.68-4.10)      \<0.01      0               0.47         REM
  Subgroup 4: colon cancer               4     1186       2.99(2.08-4.31)      \<0.01      6               0.36         REM
  Rectal cancer                          2     399        2.41(0.91-6.32)      0.08        53              0.14         REM
  Colorectal cancer                      3     1105       1.64(1.10-2.43)      0.02        10              0.33         REM
  Subgroup 5:study quality score\>6      3     911        2.43(1.22-4.84)      0.01        55              0.11         REM
  Study quality score≤6                  6     1779       2.32(1.54-3.50)      \<0.01      42              0.12         REM
  Disease-free survival (DFS)            10    8438       1.73(1.50-1.99)      \<0.01      6               0.38         FEM
  Subgroup 1: Asian                      8     3735       1.92(1.57-2.34)      \<0.01      0               0.56         FEM
  Non-Asian                              5     4703       1.55(1.27-1.90)      \<0.01      17              0.30         FEM
  Subgroup 2: LVI positive rate \>15 %   4     1485       1.91(1.34-2.72)      \<0.01      17              0.30         FEM
  LVI positive rate ≤15 %                9     6953       1.69(1.45-1.98)      \<0.01      9               0.36         FEM
  Subgroup 3: sample size\>200           10    8052       1.73(1.50-2.00)      \<0.01      16              0.29         FEM
  Sample size≤200                        3     386        1.66(0.72-3.83)      0.24        4               0.35         FEM
  Subgroup 4: colon cancer               5     2454       1.86(1.35-2.55)      \<0.01      11              0.34         REM
  Rectal cancer                          2     2873       1.91(0.95-3.82)      0.07        70              0.07         REM
  Colorectal cancer                      6     3111       1.64(1.39-1.94)      \<0.01      0               0.51         REM
  Subgroup 5:study quality score\>6      5     2266       2.09(1.57-2.77)      \<0.01      0               0.57         FEM
  Study quality score≤6                  7     3523       1.72(1.41-2.11)      \<0.01      8               0.37         FEM

FEM fixed-effect model, REM random-effect model, HR hazard ratio, N number of studies, pCRT postoperative chemoradiotherapy, *P*\* *P* value of Q test for heterogeneity test, 95%CI 95%confidence interval, LVI lymphovascular invasion

Evaluation of heterogeneity {#s2_4}
---------------------------

Because of a relative higher *I*2 value for heterogeneity found in OS among the included studies (*I*2 = 46%, *p* \< 0.01), the Galbraith plot test was performed to detect the potential source of heterogeneity. The result demonstrated that there was no specific study could be the major source of heterogeneity (Figure [4](#F4){ref-type="fig"}).

![Galbraith plot analysis in overall survival](oncotarget-08-46565-g004){#F4}

Cumulative meta-analysis {#s2_5}
------------------------

Cumulative meta-analysis was performed by ordering the included studies based on publication year. The results of cumulative meta-analysis indicated the correlation between LVI and prognosis of colorectal cancer (OS and DFS) in chronologic order (Figure [5](#F5){ref-type="fig"}). The 95% CIs have become narrower with increased sample sizes, indicating that the accuracy of the estimates was increasing by the continuous inclusion of studies.

![Forest plot of cumulative meta-analysis of the association of lymphovascular invasion with overall survival (**A**) and disease free survival (**B**) in colorectal cancer patients.](oncotarget-08-46565-g005){#F5}

Sensitivity analysis and publication bias {#s2_6}
-----------------------------------------

Sensitivity analysis was carried out on OS and DFS to assess the stability of the results by sequentially excluding each study in one turn. In present analysis, no study could possibly affect the pooled risk estimate (Figure [6](#F6){ref-type="fig"}).

![The results of sensitivity analysis of overall survival (**A**) and disease free survival (**B**) showing the effect of each study on the overall estimate by sequentially excluding one study in one turn.](oncotarget-08-46565-g006){#F6}

Meanwhile, visual assessment of funnel plots (Figure [7](#F7){ref-type="fig"}), as well as Begg\'s (Figure [8](#F8){ref-type="fig"}) and Egger\'s test (Figure [9](#F9){ref-type="fig"}) on OS and DFS were performed to assess the publication bias of the included researches. No significant asymmetrical distributions were observed in both groups. No evidence of publication bias was detected by Begg\'s and Egger\'s test (OS: *P* = 0.754, *P* = 0.291; DFS: *P* = 0.583, *P* = 0.254 respectively). Three possible missing studies in OS group and two in DFS group were identified by the trim-and-fill method using fixed-effect model (Figure [10](#F10){ref-type="fig"}). These missing studies would not change the trend of the results, so our results were reliable. (OS: HR = 1.742, 95% CI: 1.434-2.115; DFS: HR = 1.705, 95% CI: 1.482-1.961).

![Funnel plot analysis\
**A**. Funnel plot analysis of 9 studies on overall survival. **B**. Funnel plot analysis of 13 studies on disease free survival.](oncotarget-08-46565-g007){#F7}

![Begg\'s funnel plot on overall survival (A) and disease free survival (B)](oncotarget-08-46565-g008){#F8}

![Egger\'s publication bias plot on overall survival (A) and disease free survival (B)](oncotarget-08-46565-g009){#F9}

![Trim-and-fill funnel plot on overall survival (A) and disease free survival (B)](oncotarget-08-46565-g010){#F10}

DISCUSSION {#s3}
==========

Adjuvant chemotherapy remains controversial in early stage (stage I/II) colorectal cancer, especially who would benefit from adjuvant chemotherapy \[[@R27], [@R28]\]. Uncertainty on the benefit of adjuvant chemotherapy in patients with early stage disease is owing to the fact that which patients at high risk of recurrence are unknown \[[@R29]\]. Hence identification of high-risk stage I/II colorectal cancer patients becomes a clinical concern.

A massive of clinicopathologic features have been associated with a high risk of recurrence and death: tumor stage T4, small number of lymph nodes retrieved, poor differentiation, bowel obstruction, extensive intratumoral necrosis, emergency setting, positive LVI or perineural invasion, and elevated preoperative CEA \[[@R30]--[@R33]\]. According to the NCCN guidelines, high risk features for rectal cancer include positive margins, lymphovascular invasion, poorly differentiated tumors, or sm3 invasion. Moreover, poorly differentiated histology, lymphovascular invasion, bowel obstruction, \< 12 lymph nodes examined, perineural invasion, localized perforation, or close, indeterminate, or positive margins are considered as high risks for colon cancer(see at [www.NCCN.org](http://www.NCCN.org)). From the list above, LVI tends to be an important prognosis predictor after resection of early stage CRC. However, there are no data in high-risk stage II patients that correlate risk features and selection of chemotherapy. The benefit of adjuvant chemotherapy does not improve survival by more than 5% \[[@R2], [@R34]\]. There is no consensus on the necessity for adjuvant chemotherapy in patients with high-risk stage II cancer \[[@R22], [@R35], [@R36]\], whereas most clinicians in China tend to use it for them. In early stage CRC, conflicting study results and insufficient high level evidence regarding the association between LVI and survival data make it necessary to perform a quantitative meta-analysis.

To the best of our knowledge, the present meta-analysis is the first study to provide a system review and meta-analysis on prognostic significance of LVI in early stage (stage I/II) CRC. The included 19 studies and 9881 participants significantly enhanced the statistical power and provided more reliable results. Our results demonstrated that LVI has an unfavorable effect on OS and DFS in patients with early stage CRC. Moreover, the prognostic value was not altered by subgroup analysis based on district (Asian *vs*. non-Asian patients), LVI positive rate (≤15 *vs*. \> 15 %), sample sizes (≤190 *vs*. \> 200), tumor site (colon *vs*. rectum *vs*. colorectum) and study quality (≤6 *vs*. \> 6). Postoperative adjuvant chemotherapy has been shown to prolong DFS or/and OS in some stage II patients \[[@R34], [@R37]\], besides NCCN guidelines recommend patients with high-risk stage II colorectal cancer should be considered for adjuvant chemotherapy. Thus it is reasonable to consider adjuvant chemotherapy for stage II patients in LVI positive status. The current NCCN Guidelines have not identified stage I patients who have a high risk of recurrence and this stage patients are not recommended for adjuvant chemotherapy. We suggest imposing stricter surveillance on stage I patients in LVI positive status.

Although Artac M et al. suggested that LVI was not an independent risk factor for survival \[[@R7]\]. A potential value of LVI may be useful in identifying tumors with occult lymph node metastasis \[[@R38], [@R39]\], for high-risk patients with node negative (stage I/II) tumors warranting adjuvant chemotherapy \[[@R32], [@R40]\]. As we known, 12 lymph nodes or more must be surgically resected to achieve accurate staging \[[@R41]\]. Lymph node harvest is influenced by many factors, such as the extent of surgical resection, recovery from the resected specimen, and counts of microscopic slides \[[@R42], [@R43]\]. Twelve-node harvest is sometimes difficult to achieve in daily surgical practice, thus will result in stage migration. Because LVI correlates well with the status of lymph node metastasis and disease staging \[[@R21], [@R44]\], which make it possible to be a supplement for those understaged patients.

The incidence of LVI reported in the present study ranged from 5.2% to 30.3%. The figure was significantly higher in non-Asian region than in Asian region (*p* \< 0.05), and the difference in geographic setting had not been reported previously. The wide variation in LVI positive rates may due to many factors, including different geographic setting, differences in the characteristics of tumors, different criteria for LVI presence, and variations in the use of special stains or immunohistochemical (IHC) staining. Furthermore, the College of American Pathologists' consensus statement did not recommend the use of any special stains or immunohistochemical stains to diagnose vessel invasion \[[@R45]\]. The status of LVI was mainly assessed by conventional hematoxylin and eosin (H&E) staining method in the included studies. One major challenge of this method is that the identification of LVI is subjective and inconsistency \[[@R46]\]. Interobserver variability in diagnosis of LVI was substantial on H&E slides and did not improve upon use of IHC staining for CD31 and D2-40 \[[@R47]\]. On the contrary, some investigators added IHC staining to improve accuracy rate \[[@R10], [@R48]\]. Another problem with H&E staining method is hard to distinguish lymphatic vessels invasion from blood vessel invasion (BVI) \[[@R46]\]. In the present study, we combined blood vessel invasion and lymphatic vessels invasion into lymphovascular invasion. We were aware that a study by Liang P reported that only lymphatic vessels invasion is associated with lymph node metastasis, and BVI is associated with distant recurrence in the manner of immunohistology \[[@R48]\].

Several potential limitations affect the results of this meta-analysis. First, all included studies were observational studies, and some of the sample sizes were relatively small. Second, several studies were excluded due to insufficient data to determine the correlation coefficients. One study included was unable to access full-text with sufficient data to calculate from abstract, but we could not get more detail information \[[@R9]\]. Finally, rare study compared the effect of adjuvant chemotherapy in the stage II patients with LVI positive status. More randomized controlled trials (RCTs) should be performed to validate the benefit form adjuvant chemotherapy for stage I/II CRC patients with LVI positive.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

A systematic search of the PubMed, Web of Science, and Embase databases was performed to identify all relevant articles published up to 10 Dec 2016 with the limits of English. The following Medical Subject Heading (MeSH) terms or keywords were used: "colorectal neoplasms \[MeSH Terms\] OR colonic neoplasms \[MeSH Terms\] OR rectal neoplasms \[MeSH Terms\] " AND "lymphovascular invasion OR lymphovascular permeation". Moreover, we also check for potentially relevant studies through screening the references of the relevant articles.

Inclusion criteria {#s4_2}
------------------

All studies were required to meet the following criteria: (1) the diagnosis of CRC and LVI were based on pathological examination (2) the assessment of the relationships between PVI and the prognosis of CRC patients with stage I/II was reported with overall survival (OS) or/and disease-free survival (DFS), and (3) a hazard ratio (HR) was reported with 95% confidence interval (CI) or had sufficient data to estimate the HR and 95 % CI if not directly presented. When results reported from the same patient population, the most recent study or the largest dataset was included.

Abstracts and reports from meetings were excluded. Articles in which the outcomes of interest were not reported or from which it was impossible to calculate outcomes from the original data were also excluded.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two authors (H. Yuan and J.B. Xu) independently reviewed each eligible study and extracted the data. If any disagreements existed, they were resolved by discussion. Data retrieved from the articles included the first author\'s name, publication year, patient characteristics(number, sex, age, duration of follow-up, community), tumor site, LVI positive rate, study design, TNM staging, treatment characteristics \[neoadjuvant chemoradiotherapy (nCRT) and postoperative chemoradiotherapy (pCRT)\], and outcomes (OS and DFS). The quality assessment of including studies was based on the criteria of the Newcastle-Ottawa Quality Assessment scale (NOS) \[[@R49]\]. The study with NOS scores \> 6 was regarded as high-quality studies.

Statistical analysis {#s4_4}
--------------------

Meta-analysis was performed in line with the PRISMA guidelines \[[@R50]\]. Pool meta-analysis for OS/DFS was performed by using the Review Manager 5.3 software. The pooled HR and 95 % CI were calculated using the method of inverse variance and the *P* value threshold was set at 0.05. Heterogeneity was assessed by a chi-square-based Q statistical test and the *I*2 value. When *P* was \< 0.10 or/and the *I*2 value was \> 50 %, it meant significant heterogeneity between the studies and a random-effect model could be used; otherwise, a fixed-effect model was used \[[@R51]\]. Subgroup analysis, sensitivity analysis, publication bias and meta regression were performed using STATA 12.0 software.

Publication bias was assessed using a funnel plot. Subgroup analyses were performed by geographic setting, treatment, TNM staging, tumor site, LVI positive rate, and study quality. The difference of the incidence of LVI between in non-Asian region and in Asian region was performed by independent T-test.

CONCLUSIONS {#s5}
===========

In conclusion, this meta-analysis indicated that LVI is a poor prognostic factor for stage I/II CRC patients. Stage II patients with LVI positive should be considered for treatment with effective adjuvant therapies, and stricter surveillance may be imposed on stage I patients in LVI positive status.
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